![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » RESULTS OF EFAPROXYN STUDY PUBLISHED
RESULTS OF EFAPROXYN STUDY PUBLISHED
September 2, 2005
Allos Therapeutics has announced the publication of results from its Phase II multicenter study of efaproxyn in patients with unresectable non-small cell lung cancer (NSCLC) receiving sequential chemoradiotherapy (S-CRT). Results from the study, which were reported in the Journal of Clinical Oncology, suggest that the addition of efaproxyn to S-CRT may improve survival over S-CRT alone without increasing radiation toxicity rates.
Authors of the manuscript compared the safety and efficacy of the drug when administered with S-CRT in patients with unresectable NSCLC relative to data from a Phase III, Radiation Therapy Oncology Group (RTOG) 94-10 study. Results of the analysis indicate that patients in the study tended to have better survival than patients with similar characteristics in the RTOG 94-10 study. Median survival of patients treated in the efaproxyn study was 20.6 months, as compared to a median survival of 15.1 months for patients in the S-CRT arm of the RTOG 94-10 study and 17.9 months in the concurrent chemoradiotherapy arm of the RTOG 94-10 study.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct